Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center
Articles by Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

Heinz-Josef Lenz, MD, FACP, discusses the prognostic value of HER2 expression in patients with KRAS wild-type metastatic colorectal cancer.

Heinz-Josef Lenz, MD, FACP, discusses the rationale for the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.

Future Directions in Later Line Therapy for mCRC
ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center 
Key Trials in mCRC: I/O Combination Therapies
ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center 
Role of I/O Combination Therapies in mCRC
ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center 
Using I/O in MSI-H Tumors in mCRC
ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center 
Sequencing in mCRC: Later-Line Therapies
ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center 
Therapeutic Agents in Relapsed/Refractory mCRC
ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center 
CORRECT, RECOURSE, and ReDOS Trials in mCRC
ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center 
Later Lines of Therapy for mCRC
ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center 
Second-Line Treatment for mCRC
ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center 
Initiating Therapy for mCRC
ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center 
Continuum of Care for Metastatic CRC
ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center 
Heinz-Josef Lenz, MD, FACP, discusses the updated findings from the phase 2 CheckMate-142 trial in previously untreated patients with microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).

Heinz-Josef Lenz, MD, FACP, discusses updated results from the phase II CheckMate-142 trial in metastatic colorectal cancer.

Heinz-Josef Lenz, MD, FACP, discusses the safety profile of nivolumab plus ipilimumab in the phase II CheckMate-142 trial for treatment-naïve patients with microsatellite instability–high/mismatch repair deficient colorectal cancer.

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the need for new treatment strategies in colorectal cancer.

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses combinations with targeted agents in colorectal cancer.

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses immunotherapy in gastrointestinal cancers.